Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05855109 · ClinicalTrials.gov registry record
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 1,304
- Enrollment target
NCT05855109: Completed study, sponsored by Boehringer Ingelheim.
NCT05855109 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,304 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05855109 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 1,304 participants
- Enrollment target
Study Summary
The overall aim of the study is to develop and validate a Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD) clinical prediction model (screening tool) based on risk factors to guide screening for ILD in patients with RA using High Resolution Computed Tomography (HRCT).
Primary Outcome
The endpoint of the model will be to recommend screening HRCT scan based on risk factors.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,304 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2025-06-26 |
What the finished NCT05855109 record still lists
NCT05855109 is an observational study that tracks outcomes without assigning an intervention. Its 1,304 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05855109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05855109 about?
NCT05855109 is a clinical study titled "Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors". The overall aim of the study is to develop and validate a Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD) clinical prediction model (screening tool) based on risk factors to guide screening for ILD in patients with RA using High Resolution Computed Tomography (HRCT).
What is the current status of trial NCT05855109?
This trial is currently completed. The enrollment target is 1,304 participants. The study started on 2023-11-27. Estimated completion is 2025-06-26.
Who is sponsoring clinical trial NCT05855109?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04171323 · 1,305 participants · NA
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
- NCT06517901 · 1,306 participants · NA
Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI